FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 720 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How Fatty Liver Disease Helps Cancer Thrive in the Liver July 6, 2023 New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo... September 13, 2019 Spotlight On: Exercise Physiologists in Cancer Care November 16, 2023 FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer September 14, 2022 Load more HOT NEWS FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma New Survey Highlights the Role of Clinical Practice Guidelines to Improve... Reflecting On My Time As the Cancer.Net Editor in Chief 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’
